Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HEXA | P06865 | 1/20 | 0.34 |
| ▸ | HEXB | P07686 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455057 | 0.86 | KDM4E (0.39) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL11614509 | 0.84 | NPC1 (0.46) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL10813438 | 0.75 | ALDH1A1 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6302015 | 0.75 | NPC1 (0.42) | CA12CA9SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL5501308 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL9813218 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL17842409 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL28061028 | 0.70 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL9244967 | 0.70 | TERT (0.43) | SMN1; SMN2KDM4EHEXAHEXBKMT2A | |
| SCHEMBL28061568 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621775-A | 2-amino-5-hydroxytetrahydronaphthalene derivative containing hydroxypyridone side chain, preparation and application thereof | 浙江大学 | 2023-08-22 | — | — | CN | claimed |
| CN-116621775-A | 2-amino-5-hydroxytetrahydronaphthalene derivative containing hydroxypyridone side chain, preparation and application thereof | 浙江大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-102863432-B | CFTR conditioning agent | 沃泰克斯药物股份有限公司 | 2016-09-07 | — | — | CN | disclosed |
| CN-104447716-A | Modulators of CFTR | VERTEX PHARMA | 2015-03-25 | — | — | CN | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | CA12 1244/4885CA1 733/4885CA2 429/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | CA12 1571/4885CA1 1051/4885CA2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.